4//SEC Filing
Van Strydonck, Gerald E. 4
Accession 0000891839-20-000030
CIK 0001205922other
Filed
Jan 14, 7:00 PM ET
Accepted
Jan 15, 4:20 PM ET
Size
12.5 KB
Accession
0000891839-20-000030
Insider Transaction Report
Form 4
VACCINEX, INC.VCNX
Van Strydonck, Gerald E.
Director
Transactions
- Award
Stock Option (Right to Buy)
2019-06-30+2,385→ 2,385 totalExercise: $5.52From: 2019-06-30Exp: 2029-06-29→ Common Stock (2,385 underlying)
Holdings
- 7,718
Stock Option (Right to Buy)
Exercise: $7.78From: 2020-05-15→ Common Stock (7,718 underlying) - 7,500
Stock Option (Right to Buy)
Exercise: $14.90Exp: 2023-03-06→ Common Stock (7,500 underlying) - 2,501
Stock Option (Right to Buy)
Exercise: $5.26Exp: 2029-03-30→ Common Stock (2,501 underlying) - 4,500
Stock Option (Right to Buy)
Exercise: $10.00Exp: 2020-03-06→ Common Stock (4,500 underlying) - 6,396
Stock Option (Right to Buy)
Exercise: $13.60Exp: 2027-09-15→ Common Stock (6,396 underlying)
Footnotes (3)
- [F1]Exercisable in full as of the date of this report.
- [F2]This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
- [F3]Pursuant to the Issuer's Director Compensation Program, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the second quarter of 2019. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable.
Documents
Issuer
VACCINEX, INC.
CIK 0001205922
Entity typeother
Related Parties
1- filerCIK 0001748247
Filing Metadata
- Form type
- 4
- Filed
- Jan 14, 7:00 PM ET
- Accepted
- Jan 15, 4:20 PM ET
- Size
- 12.5 KB